VEGFA and neoplasm: A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody can bind VEGF-A to inhibit its binding to VEGF receptor-2 (VEGFR-2), and then inhibit the biological effects of VEGF, including affecting vascular permeability, proliferation and endothelial cell migration and survival, so as to inhibit tumor angiogenesis, growth and metastasis